NUF2 and hepatocellular carcinoma: In particular, for HCC, we found that the DSS (Figure 2A, HR=2.99, 95% CI=1.89 to 4.75, P=1e-06), PFS (Figure 2B, HR=1.94, 95% CI=1.41 to 2.66, P=3.7e-05), OS (Figure 2C, HR=2.32, 95% CI=1.61 to 3.34, P=3.9e-06), and RFS (Figure 2D, HR=1.95, 95% CI=1.36 to 2.78, P=2e-04) were significantly reduced when the expression level of Nuf2 was high, indicating that active transcription of Nuf2 might cause health risks, and these genes could be potential prognostic biomarkers for HCC patients.